News

Cambridge, UK, 26 August 2020: Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potential of the team, and its iPSC (induced pluripotent stem cell) technologies, products and services.

We are delighted to announce that Chris Kirton joins us as our Chief Operating Officer; a senior operations leader with over 15 years of drug development, commercial and operational management experience in both industry and academia. Chris joins us from a leading supplier in the biotech industry and takes up his leadership role at Axol, bringing with him his extensive operational experience at the highest levels, focusing Axol's position and supporting growth within the Human iPSC-Derived Stem Cell market.

✓ Our Booth #760
✓ Our Workshop (find out more)
✓ Our Poster (find out more)

Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

Axol Bioscience is presenting at the two-day seminar hold by Evercyte and Altetox in Vienna, from 30-31 October. Book your ticket today.

We are delighted to announce plans to open a new operational hub in the United States. The site will open in the fall of 2018 and will help to support Axol’s customer base in the United States and Canada.

Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

Axol Bioscience is meeting Metrion Biosciences for a whole day stem cell event, on May 23, 2018. Don't miss the opportunity to see some excellent scientific presentations.

Our team has spent the first few months of 2018 working hard to introduce an exciting new range of products to the Axol catalog. As well as the Primary and iPS derived human cells Axol is know for; we can now offer researchers the convenience of sourcing antibodies, kits and other reagents in one place.

We are attending the ELRIG Research & Innovation Meeting 2018 in Cambridge, UK, from 17-18 April 2018. We will be available throughout the conference at booth 7, during our Spotlight Sessions about Microglia and Neural Cells as well as our Poster. Join us!

We are attending the SOT Annual Meeting 2018 in Texas, from 11-15 March 2018. We will be available throughout the conference at booth 760 as well as in our workshop, March 12. Join us!

Since a funding injection by our investors in 2017, we have been working hard to double our manufacturing capacity and bring some exciting new products to market. Cells will always be the (beating) heart of what we do at Axol, but we know that until now our customers have had to look elsewhere for antibodies, kits and other reagents.

Are you popping over to Cambridge for the 6th Cambridge International Stem Cell Symposium? Why not to join our networking event the night before?

Are you attending SLAS 2018? Meet with our product experts and discuss about Axol's latest innovations and technologies. We will be at booth #450, or you can find us at our spotlight session or our workshop.

Are you attending SfN 2017?. Check out Axol's latest product innovations on our booth as well as in our workshop.

Private equity firm Calculus Capital, a leading EIS and VCT investor, has further expanded its life science portfolio, by investing £2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells.

We hereby announce that ID Pharma Co., Ltd., a wholly owned subsidiary of our company (hereinafter "ID Pharma") has entered into a licensing agreement with Axol Bioscience to enable them to produce iPS cells using the CytoTune®-iPS technology ( ¹ ) owned by ID Pharma, and to supply and sell differentiated cells derived from these iPS cells as research products.

Cambridge, UK, 26 July 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells, and Metrion Biosciences, a specialist ion channel drug discovery business, have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias. This is in accordance with the FDA’s Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to revise cardiac safety testing regulations.

Under the terms of the agreement, Metrion will use Axol’s human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing and translational phenotypic assays. Combining Metrion's contract research services and assay development capabilities with Axol’s human iPSC-derived cells and culture reagents will provide a source of well-validated, CiPA-compliant stem cell-derived assays and services for use in predictive toxicology as well as drug discovery screening.

BIRMINGHAM, CAMBRIDGE, HUDDERSFIELD (UK), HANNOVER (Germany), BARCELONA (Spain), 9 June 2016: The MESO-BRAIN consortium has received a prestigious award of €3.3 million in funding from the European Commission as part of its Future and Emerging Technology (FET) scheme. The project aims to develop three-dimensional (3D) human neural networks with specific biological architecture, and the inherent ability to interrogate the network’s brain-like activity both electrophysiologically and optically. It is expected that the MESO-BRAIN will facilitate a better understanding of human disease progression, neuronal growth and enable the development of large-scale human cell-based assays to test the modulatory effects of pharmacological and toxicological compounds on neural network activity. The use of more physiologically relevant human models will increase drug screening efficiency and reduce the need for animal testing.